



# Long-term neurocognitive and psychiatric consequences of COVID-19 in patients discharged from critical care units.

Preliminary results from the NPQCOVID Cohort Study of AIRR

F. León<sup>1</sup>, C. Astudillo<sup>2,3</sup>, C. Méndez<sup>2,3</sup>, F. Palacios<sup>1</sup>, P. Toro<sup>1</sup>, C. Caneo<sup>1,3</sup>©

<sup>1</sup> Departamento de Psiquiatría, Pontificia Universidad Católica de Chile

<sup>2</sup> Departamento de Ciencias de la Salud, Pontificia Universidad Católica de Chile

<sup>3</sup> AIRR: Advance Interdisciplinary Rehabilitation Register Covid-19 Working Group.

Contact: [cmcaneo@uc.cl](mailto:cmcaneo@uc.cl)

## BACKGROUND

- New or worsening cognitive impairment commonly occurs and persists in survivors of intensive care unit stay (1), a problem also observed in COVID-19 survivors.
- No studies on this matter have been conducted in Latino America.
- Aim: Describe neurocognitive performance in the short & long-term in patients discharged from Critical Care Units (CCU) after severe COVID-19 disease.

## WHAT WAS DONE?

- **Design:** Cohort study (recruiting).
- **Sample:** 40 out of 88 patients assessed with Montreal Cognitive Assessment (MoCA<sup>®</sup>) test by our C-L team prior discharged from CCU of Hospital Clínico Red Salud UC Christus between June and October 2020.
- **12 months follow-up primary outcome:** MoCA<sup>®</sup>.
- **12 months follow-up secondary outcome:** Cambridge Neuropsychological Test Automated Battery (CANTAB<sup>®</sup>), 6 minutes- walk test (6MWT).
- **Clinical Trials:** NCT05019300.

References:

1. Hosey MM, Needham DM. Survivorship after COVID-19 ICU stay. Nat Rev Dis Primers. 2020 Jul 15;6(1):60.

2. \*Gaete M, et al. Standardized results of the Montreal Cognitive Assessment (MoCA) for neurocognitive screening in a Chilean population. Neurologia (Engl Ed). 2020 Nov 5;S0213-4853(20)30294-2.

\*Validated cut-off score for cognitive impairment in Chile.

## WHAT DID WE FIND?

- **Demographics:** 88 patients, mean age 62,21 (SD 16,01), 55% male.
- **Preliminary results of primary outcome:**
  - Overall MoCA<sup>®</sup> score at discharge (n=88) of 22,13 points (SD 7,87). 25% scored  $\leq 21$  points\*
  - Overall MoCA<sup>®</sup> at 12 months follow up (n=40) 23,6 points (SD 6,82). 20% scored  $\leq 21$ \*.

- **Preliminary analysis of secondary outcomes, (CANTAB<sup>®</sup>):** Figures 1 & 2:
  - Non-normal distribution of z-scores of CANTAB<sup>®</sup> tests, showing a negative skew distribution.
  - MoCA<sup>®</sup> scores  $\leq 21$  versus  $> 21$  show different distribution of 6MWT at 12 month follow up.




Figure 1. CANTAB<sup>®</sup> tests z scores distribution.




Figure 2. Overall 6MWT in normal and altered MoCA<sup>®</sup> scores.

## WHAT DOES THIS MEAN?

- MoCA<sup>®</sup> average score remains stable between discharge from hospital and 12 months follow-up assessments.
- MoCA<sup>®</sup> score  $\leq 21$  at hospital discharge may be related to lower performance on 12-month 6MWT, and thus, lower endurance and aerobic capacity in the long term.
- Patients discharged from severe COVID-19 disease are in need of specialized care even in the long term.



## TAKE HOME MESSAGES

- COVID-19 patients with neurocognitive impairment at discharge may show a persistence of cognitive impairment in several domains in the long term.
- MoCA<sup>®</sup> at discharge could be a putative predictor for aerobic capacity and endurance.
- Long-term follow up studies are needed to inform prompt and personalized continuity of care in this population.

